Abstract
Inflammatory bowel disease (IBD) is a group of chronic, relapsing disorders of the gastrointestinal (GI) tract that significantly affect patient's quality of life. The main goals of IBD treatment are long-lasting clinical remission without serious adverse events. The lack of fully effective treatment urges researchers to seek for new therapeutic strategies and design of novel anti-inflammatory compounds.In this review, we focus on the latest advances in the IBD therapy. We characterize the clinical efficacy and mechanism of action of stem cell-, antibody- and small molecule-based methods of treatment that already reached clinic or are currently evaluated in clinical studies. The scope of this article is on agents targeting interleukin 12 and 23, integrins α4β7 and αEβ7, mucosal vascular addressin cell adhesion molecule, janus kinases, sphingosine-1-phosphate and toll-like receptor 9. We also describe recent advances in the discovery of biomarkers in IBD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.